SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-135066
Filing Date
2023-05-04
Accepted
2023-05-04 07:37:01
Documents
13
Period of Report
2023-05-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d108671d8k.htm   iXBRL 8-K 25424
2 EX-99.1 d108671dex991.htm EX-99.1 86510
  Complete submission text file 0001193125-23-135066.txt   245703

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA itci-20230504.xsd EX-101.SCH 2895
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20230504_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20230504_pre.xml EX-101.PRE 10842
7 EXTRACTED XBRL INSTANCE DOCUMENT d108671d8k_htm.xml XML 3208
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 23886522
SIC: 2834 Pharmaceutical Preparations